Botanix Pharmaceuticals (ASX:BOT) is a dermatology company focused on the development and commercialization of innovative and effective topical treatments for a range of serious skin conditions. The company has a portfolio of products in clinical development, including its lead product, Sofpironium Bromide, which is currently in Phase 3 clinical trials for the treatment of primary axillary hyperhidrosis (excessive underarm sweating). Botanix is also developing other products for the treatment of atopic dermatitis, rosacea, and acne. The company's products are based on a proprietary technology platform called Australasian Botanical Products (ABP), which harnesses the power of natural plant extracts to develop new and effective treatments for skin conditions.